HBM Holdings Limited announced that China’s National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for HBM7004, a B7H4xCD3 bispecific antibody intended for the treatment of advanced solid tumors. The acceptance follows the U.S. Food and Drug Administration’s clearance on 8 May 2026 to begin a first-in-human Phase I trial, underscoring regulatory momentum for the program in two major markets.

HBM7004 was engineered through the company’s proprietary HBICE® platform to provide a differentiated immunotherapy approach that balances efficacy and safety. Preclinical studies demonstrated tumor-localized, B7H4-dependent T-cell activation, strong anti-tumor efficacy, notable in-vivo stability, and lower systemic toxicity. Further, when combined with a B7H4x4-1BB bispecific antibody at low effector-to-target cell ratios, HBM7004 produced a pronounced synergistic effect, suggesting a favorable therapeutic window.

Management indicated that the latest regulatory milestone highlights the versatility of the HBICE® platform but cautioned that successful development and commercialization are not guaranteed. Investors are advised to exercise care when dealing in the company’s shares.